Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor treatment options, emphasizing the need for novel therapeutic targets. Hub proteins have high connectivity (i.e., many interaction partners) and often act as central biological regulators. Here, we aimed to identify hub proteins with potential...
Foram Vyas, Virginie Defamie, Kelvin Yeung et al.· Cancer Research· 0 citations
Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....
W. Quan, D. Henault, S. M. Hasnain et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...
A. Habowski, Fatim M. Kouassi, James A. Rouse et al.· Cancer Research· 0 citations
This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.
J. Romero, Yi-Fan Wang, Edward Shanbedi et al.· Cancer Research· 0 citations
The role of tumoral HMGA2 expression in controlling an immunosuppressive TME is demonstrated, a potential biomarker to determine TME phenotype in PDAC patients is highlighted and a novel subtype-specific immunomodulatory therapy is introduced.
Naomi Yamamoto, S. Dobersch, Tess M. Robertson et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.